Chiasma to Report Third Quarter 2020 Results on November 5
October 29, 2020 08:00 ET
|
Chiasma
NEEDHAM, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio...
Chiasma Announces Planned Transition of Former CEO
October 01, 2020 07:00 ET
|
Chiasma
NEEDHAM, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize...
Chiasma to Participate in Two September Investor Conferences
September 08, 2020 08:00 ET
|
Chiasma
NEEDHAM, Mass., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to...
Chiasma Announces U.S. Commercial Launch and Availability of MYCAPSSA®, the First and Only Oral Somatostatin Analog for Patients with Acromegaly
August 31, 2020 08:00 ET
|
Chiasma
NEEDHAM, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to...
Chiasma Announces Publication of Pivotal Data from the Phase 3 CHIASMA OPTIMAL Clinical Trial in the Journal of Clinical Endocrinology & Metabolism
August 17, 2020 08:00 ET
|
Chiasma
NEEDHAM, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company utilizing its delivery platform technology to develop oral therapies to...
Chiasma Reports Second Quarter 2020 Results and Significant Progress on Launch Preparedness
August 10, 2020 16:05 ET
|
Chiasma
MYCAPSSA® U.S. commercial launch planned for the fourth quarter On track to announce MPOWERED Phase 3 trial topline data in the fourth quarter Company to host conference call today, August...
Chiasma to Report Second Quarter 2020 Results on August 10
August 03, 2020 16:01 ET
|
Chiasma
NEEDHAM, Mass., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial stage biopharmaceutical company, today announced that it will host a conference call and live audio...
Chiasma Announces 48-Week Safety and Efficacy Data from the Open-Label Extension Study of its CHIASMA OPTIMAL Phase 3 Trial Evaluating MYCAPSSA® in Patients with Acromegaly
July 27, 2020 16:01 ET
|
Chiasma
-- The mean of the IGF-1 levels for the population of all MYCAPSSA treated patients that completed the 36-week core CHIASMA OPTIMAL trial and continued into the open-label extension (OLE) (n=19) was...
Chiasma Announces Pricing of a Public Offering of $70 Million of Common Stock and Pre-Funded Warrants
July 01, 2020 09:05 ET
|
Chiasma
NEEDHAM, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its...
Chiasma Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 30, 2020 16:30 ET
|
Chiasma
NEEDHAM, Mass., June 30, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial biopharmaceutical company focused on developing and commercializing oral therapies utilizing its...